Proactiveinvestors USA & Canada Kazia Therapeutics Ltd https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Kazia Therapeutics Ltd RSS feed en Tue, 29 Sep 2020 11:15:39 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Kazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphoma https://www.proactiveinvestors.com/companies/news/929609/kazia-therapeutics-to-collaborate-with-dana-farber-cancer-institute-in-paxalisib-clinical-trial-for-primary-cns-lymphoma-929609.html Tue, 22 Sep 2020 01:51:00 -0400 https://www.proactiveinvestors.com/companies/news/929609/kazia-therapeutics-to-collaborate-with-dana-farber-cancer-institute-in-paxalisib-clinical-trial-for-primary-cns-lymphoma-929609.html Kazia Therapeutics bringing a vetted drug class to the brain: Edison https://www.proactiveinvestors.com/companies/news/928568/kazia-therapeutics-bringing-a-vetted-drug-class-to-the-brain-edison-928568.html Tue, 08 Sep 2020 22:33:00 -0400 https://www.proactiveinvestors.com/companies/news/928568/kazia-therapeutics-bringing-a-vetted-drug-class-to-the-brain-edison-928568.html Kazia Therapeutics directors show confidence in oncology strategy with on-market purchases https://www.proactiveinvestors.com/companies/news/927765/kazia-therapeutics-directors-show-confidence-in-oncology-strategy-with-on-market-purchases-927765.html Fri, 28 Aug 2020 04:43:00 -0400 https://www.proactiveinvestors.com/companies/news/927765/kazia-therapeutics-directors-show-confidence-in-oncology-strategy-with-on-market-purchases-927765.html Kazia Therapeutics awarded US FDA Orphan Drug Designation to paxalisib treatment for malignant glioma https://www.proactiveinvestors.com/companies/news/927303/kazia-therapeutics-awarded-us-fda-orphan-drug-designation-to-paxalisib-treatment-for-malignant-glioma-927303.html Mon, 24 Aug 2020 00:45:00 -0400 https://www.proactiveinvestors.com/companies/news/927303/kazia-therapeutics-awarded-us-fda-orphan-drug-designation-to-paxalisib-treatment-for-malignant-glioma-927303.html Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib https://www.proactiveinvestors.com/companies/news/927255/kazia-therapeutics-ceo-hails-fast-track-designation-for-paxalisib-927255.html Fri, 21 Aug 2020 09:53:00 -0400 https://www.proactiveinvestors.com/companies/news/927255/kazia-therapeutics-ceo-hails-fast-track-designation-for-paxalisib-927255.html Kazia Therapeutics soars on award of US FDA Fast Track Designation to paxalisib for glioblastoma https://www.proactiveinvestors.com/companies/news/927090/kazia-therapeutics-soars-on-award-of-us-fda-fast-track-designation-to-paxalisib-for-glioblastoma-927090.html Thu, 20 Aug 2020 06:06:00 -0400 https://www.proactiveinvestors.com/companies/news/927090/kazia-therapeutics-soars-on-award-of-us-fda-fast-track-designation-to-paxalisib-for-glioblastoma-927090.html Kazia Therapeutics hits A$1 on grant of Rare Pediatric Disease Designation to paxalisib for DIPG https://www.proactiveinvestors.com/companies/news/926080/kazia-therapeutics-hits-a1-on-grant-of-rare-pediatric-disease-designation-to-paxalisib-for-dipg-926080.html Fri, 07 Aug 2020 00:50:00 -0400 https://www.proactiveinvestors.com/companies/news/926080/kazia-therapeutics-hits-a1-on-grant-of-rare-pediatric-disease-designation-to-paxalisib-for-dipg-926080.html Kazia Therapeutics interim data from clinical studies reinforces positive efficacy signals https://www.proactiveinvestors.com/companies/news/922405/kazia-therapeutics-interim-data-from-clinical-studies-reinforces-positive-efficacy-signals-922405.html Mon, 22 Jun 2020 06:42:00 -0400 https://www.proactiveinvestors.com/companies/news/922405/kazia-therapeutics-interim-data-from-clinical-studies-reinforces-positive-efficacy-signals-922405.html Kazia Therapeutics sees 2020 as crucial inflection point for oncology programs https://www.proactiveinvestors.com/companies/news/922165/kazia-therapeutics-sees-2020-as-crucial-inflection-point-for-oncology-programs-922165.html Thu, 18 Jun 2020 00:04:00 -0400 https://www.proactiveinvestors.com/companies/news/922165/kazia-therapeutics-sees-2020-as-crucial-inflection-point-for-oncology-programs-922165.html Kazia Therapeutics working on moving its flagship Paxalisib drug into pivotal trial for registration https://www.proactiveinvestors.com/companies/news/921101/kazia-therapeutics-working-on-moving-its-flagship-paxalisib-drug-into-pivotal-trial-for-registration-921101.html Thu, 04 Jun 2020 06:09:00 -0400 https://www.proactiveinvestors.com/companies/news/921101/kazia-therapeutics-working-on-moving-its-flagship-paxalisib-drug-into-pivotal-trial-for-registration-921101.html Kazia Therapeutics presents positive interim data from paxalisib study at prestigious medical conference https://www.proactiveinvestors.com/companies/news/920773/kazia-therapeutics-presents-positive-interim-data-from-paxalisib-study-at-prestigious-medical-conference-920773.html Mon, 01 Jun 2020 02:07:00 -0400 https://www.proactiveinvestors.com/companies/news/920773/kazia-therapeutics-presents-positive-interim-data-from-paxalisib-study-at-prestigious-medical-conference-920773.html Kazia Therapeutics CEO demonstrates confidence in the company with on-market purchase https://www.proactiveinvestors.com/companies/news/920475/kazia-therapeutics-ceo-demonstrates-confidence-in-the-company-with-on-market-purchase-920475.html Wed, 27 May 2020 06:49:00 -0400 https://www.proactiveinvestors.com/companies/news/920475/kazia-therapeutics-ceo-demonstrates-confidence-in-the-company-with-on-market-purchase-920475.html Kazia Therapeutics directors extend strong support for share placement https://www.proactiveinvestors.com/companies/news/919206/kazia-therapeutics-directors-extend-strong-support-for-share-placement-919206.html Mon, 11 May 2020 05:45:00 -0400 https://www.proactiveinvestors.com/companies/news/919206/kazia-therapeutics-directors-extend-strong-support-for-share-placement-919206.html Kazia Therapeutics substantial holder BNY Mellon lifts stake to more than 25% https://www.proactiveinvestors.com/companies/news/919152/kazia-therapeutics-substantial-holder-bny-mellon-lifts-stake-to-more-than-25-919152.html Fri, 08 May 2020 04:05:00 -0400 https://www.proactiveinvestors.com/companies/news/919152/kazia-therapeutics-substantial-holder-bny-mellon-lifts-stake-to-more-than-25-919152.html Kazia Therapeutics raises $1.8 million in well supported share placement https://www.proactiveinvestors.com/companies/news/918915/kazia-therapeutics-raises-18-million-in-well-supported-share-placement-918915.html Wed, 06 May 2020 03:10:00 -0400 https://www.proactiveinvestors.com/companies/news/918915/kazia-therapeutics-raises-18-million-in-well-supported-share-placement-918915.html Kazia Therapeutics extends SPP owing to strong demand https://www.proactiveinvestors.com/companies/news/918684/kazia-therapeutics-extends-spp-owing-to-strong-demand-918684.html Mon, 04 May 2020 01:13:00 -0400 https://www.proactiveinvestors.com/companies/news/918684/kazia-therapeutics-extends-spp-owing-to-strong-demand-918684.html Kazia Therapeutics Cantrixil Phase I ovarian cancer study produces further positive data https://www.proactiveinvestors.com/companies/news/917464/kazia-therapeutics-cantrixil-phase-i-ovarian-cancer-study-produces-further-positive-data-917464.html Fri, 17 Apr 2020 04:15:00 -0400 https://www.proactiveinvestors.com/companies/news/917464/kazia-therapeutics-cantrixil-phase-i-ovarian-cancer-study-produces-further-positive-data-917464.html Kazia Therapeutics’ scientific and clinical fundamentals remain strong: Edison Investment Research https://www.proactiveinvestors.com/companies/news/917125/kazia-therapeutics-scientific-and-clinical-fundamentals-remain-strong-edison-investment-research-917125.html Tue, 14 Apr 2020 04:18:00 -0400 https://www.proactiveinvestors.com/companies/news/917125/kazia-therapeutics-scientific-and-clinical-fundamentals-remain-strong-edison-investment-research-917125.html Kazia Therapeutics raises $7.2 million in placement supported by high-quality new and existing institutional investors https://www.proactiveinvestors.com/companies/news/916974/kazia-therapeutics-raises-72-million-in-placement-supported-by-high-quality-new-and-existing-institutional-investors-916974.html Thu, 09 Apr 2020 00:20:00 -0400 https://www.proactiveinvestors.com/companies/news/916974/kazia-therapeutics-raises-72-million-in-placement-supported-by-high-quality-new-and-existing-institutional-investors-916974.html Kazia Therapeutics Phase II Paxalisib glioblastoma study shows positive overall survival signal data https://www.proactiveinvestors.com/companies/news/916754/kazia-therapeutics-phase-ii-paxalisib-glioblastoma-study-shows-positive-overall-survival-signal-data-916754.html Tue, 07 Apr 2020 03:09:00 -0400 https://www.proactiveinvestors.com/companies/news/916754/kazia-therapeutics-phase-ii-paxalisib-glioblastoma-study-shows-positive-overall-survival-signal-data-916754.html Kazia Therapeutics substantial holder increases position https://www.proactiveinvestors.com/companies/news/915262/kazia-therapeutics-substantial-holder-increases-position-915262.html Wed, 18 Mar 2020 22:14:00 -0400 https://www.proactiveinvestors.com/companies/news/915262/kazia-therapeutics-substantial-holder-increases-position-915262.html Kazia Therapeutics set to release interim paxalisib data via ASX after cancellation of AACR annual meeting https://www.proactiveinvestors.com/companies/news/915068/kazia-therapeutics-set-to-release-interim-paxalisib-data-via-asx-after-cancellation-of-aacr-annual-meeting-915068.html Tue, 17 Mar 2020 05:21:00 -0400 https://www.proactiveinvestors.com/companies/news/915068/kazia-therapeutics-set-to-release-interim-paxalisib-data-via-asx-after-cancellation-of-aacr-annual-meeting-915068.html Kazia Therapeutics finishes trial enrolment, sets date for data release https://www.proactiveinvestors.com/companies/news/914436/kazia-therapeutics-finishes-trial-enrolment-sets-date-for-data-release-914436.html Fri, 06 Mar 2020 06:07:00 -0500 https://www.proactiveinvestors.com/companies/news/914436/kazia-therapeutics-finishes-trial-enrolment-sets-date-for-data-release-914436.html Kazia Therapeutics directors buy more shares through on-market trades https://www.proactiveinvestors.com/companies/news/913486/kazia-therapeutics-directors-buy-more-shares-through-on-market-trades-913486.html Mon, 24 Feb 2020 03:29:00 -0500 https://www.proactiveinvestors.com/companies/news/913486/kazia-therapeutics-directors-buy-more-shares-through-on-market-trades-913486.html Kazia Therapeutics achieves cancer clinical program milestones in 2019 https://www.proactiveinvestors.com/companies/news/913287/kazia-therapeutics-achieves-cancer-clinical-program-milestones-in-2019-913287.html Thu, 20 Feb 2020 04:09:00 -0500 https://www.proactiveinvestors.com/companies/news/913287/kazia-therapeutics-achieves-cancer-clinical-program-milestones-in-2019-913287.html Kazia Therapeutics’ glioblastoma drug to join pivotal international trial: Edison https://www.proactiveinvestors.com/companies/news/911427/kazia-therapeutics-glioblastoma-drug-to-join-pivotal-international-trial-edison-911427.html Fri, 24 Jan 2020 01:45:00 -0500 https://www.proactiveinvestors.com/companies/news/911427/kazia-therapeutics-glioblastoma-drug-to-join-pivotal-international-trial-edison-911427.html Kazia Therapeutics gets $1.39 million R&D cash rebate https://www.proactiveinvestors.com/companies/news/909776/kazia-therapeutics-gets-139-million-rd-cash-rebate-909776.html Tue, 24 Dec 2019 02:45:00 -0500 https://www.proactiveinvestors.com/companies/news/909776/kazia-therapeutics-gets-139-million-rd-cash-rebate-909776.html Kazia Therapeutics to join international study in glioblastoma with lead program GDC-0084 https://www.proactiveinvestors.com/companies/news/908920/kazia-therapeutics-to-join-international-study-in-glioblastoma-with-lead-program-gdc-0084-908920.html Wed, 11 Dec 2019 02:26:00 -0500 https://www.proactiveinvestors.com/companies/news/908920/kazia-therapeutics-to-join-international-study-in-glioblastoma-with-lead-program-gdc-0084-908920.html Kazia Therapeutics shares surge after positive early phase II study results for GDC-0084 in brain cancer patients https://www.proactiveinvestors.com/companies/news/907687/kazia-therapeutics-shares-surge-after-positive-early-phase-ii-study-results-for-gdc-0084-in-brain-cancer-patients-907687.html Mon, 25 Nov 2019 05:56:00 -0500 https://www.proactiveinvestors.com/companies/news/907687/kazia-therapeutics-shares-surge-after-positive-early-phase-ii-study-results-for-gdc-0084-in-brain-cancer-patients-907687.html Kazia Therapeutics releases data from study of GDC-0084 into aggressive form of brain cancer https://www.proactiveinvestors.com/companies/news/907685/kazia-therapeutics-releases-data-from-study-of-gdc-0084-into-aggressive-form-of-brain-cancer-907685.html Sun, 24 Nov 2019 23:54:00 -0500 https://www.proactiveinvestors.com/companies/news/907685/kazia-therapeutics-releases-data-from-study-of-gdc-0084-into-aggressive-form-of-brain-cancer-907685.html Kazia Therapeutics raises $4 million to progress R&D programs https://www.proactiveinvestors.com/companies/news/905688/kazia-therapeutics-raises-4-million-to-progress-rd-programs-905688.html Mon, 28 Oct 2019 02:50:00 -0400 https://www.proactiveinvestors.com/companies/news/905688/kazia-therapeutics-raises-4-million-to-progress-rd-programs-905688.html Kazia Therapeutics halts trade in securities ahead of capital raising news https://www.proactiveinvestors.com/companies/news/905513/kazia-therapeutics-halts-trade-in-securities-ahead-of-capital-raising-news-905513.html Thu, 24 Oct 2019 06:30:00 -0400 https://www.proactiveinvestors.com/companies/news/905513/kazia-therapeutics-halts-trade-in-securities-ahead-of-capital-raising-news-905513.html Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference https://www.proactiveinvestors.com/companies/news/903836/kazia-therapeutics-presents-new-data-from-cantrixil-phase-1-study-in-ovarian-cancer-at-global-conference-903836.html Tue, 01 Oct 2019 02:59:00 -0400 https://www.proactiveinvestors.com/companies/news/903836/kazia-therapeutics-presents-new-data-from-cantrixil-phase-1-study-in-ovarian-cancer-at-global-conference-903836.html Kazia Therapeutics presents ovarian cancer study at conference https://www.proactiveinvestors.com/companies/news/903700/kazia-therapeutics-presents-ovarian-cancer-study-at-conference-903700.html Mon, 30 Sep 2019 01:15:00 -0400 https://www.proactiveinvestors.com/companies/news/903700/kazia-therapeutics-presents-ovarian-cancer-study-at-conference-903700.html Kazia Therapeutics to share pipeline results with market and clinicians https://www.proactiveinvestors.com/companies/news/903409/kazia-therapeutics-to-share-pipeline-results-with-market-and-clinicians-903409.html Wed, 25 Sep 2019 22:20:00 -0400 https://www.proactiveinvestors.com/companies/news/903409/kazia-therapeutics-to-share-pipeline-results-with-market-and-clinicians-903409.html Kazia Therapeutics to present on phase II study of GDC-0084 in glioblastoma at Neuro Oncology meeting in France https://www.proactiveinvestors.com/companies/news/903105/kazia-therapeutics-to-present-on-phase-ii-study-of-gdc-0084-in-glioblastoma-at-neuro-oncology-meeting-in-france-903105.html Fri, 20 Sep 2019 02:12:00 -0400 https://www.proactiveinvestors.com/companies/news/903105/kazia-therapeutics-to-present-on-phase-ii-study-of-gdc-0084-in-glioblastoma-at-neuro-oncology-meeting-in-france-903105.html Kazia Therapeutics wins ANZLF Trans-Tasman Innovation and Growth award https://www.proactiveinvestors.com/companies/news/902639/kazia-therapeutics-wins-anzlf-trans-tasman-innovation-and-growth-award-902639.html Fri, 13 Sep 2019 00:48:00 -0400 https://www.proactiveinvestors.com/companies/news/902639/kazia-therapeutics-wins-anzlf-trans-tasman-innovation-and-growth-award-902639.html Kazia Therapeutics confirms successful completion of phase I study of its childhood cancer drug https://www.proactiveinvestors.com/companies/news/902547/kazia-therapeutics-confirms-successful-completion-of-phase-i-study-of-its-childhood-cancer-drug-902547.html Thu, 12 Sep 2019 04:57:00 -0400 https://www.proactiveinvestors.com/companies/news/902547/kazia-therapeutics-confirms-successful-completion-of-phase-i-study-of-its-childhood-cancer-drug-902547.html Kazia Therapeutics' cancer drug trials lift valuation to $137 million or $2.20 a share, according to Edison https://www.proactiveinvestors.com/companies/news/902275/kazia-therapeutics--cancer-drug-trials-lift-valuation-to-137-million-or-220-a-share-according-to-edison-902275.html Mon, 09 Sep 2019 07:01:00 -0400 https://www.proactiveinvestors.com/companies/news/902275/kazia-therapeutics--cancer-drug-trials-lift-valuation-to-137-million-or-220-a-share-according-to-edison-902275.html Kazia Therapeutics a top-10 finalist in ANZLF Trans-Tasman Innovation and Growth Awards https://www.proactiveinvestors.com/companies/news/902186/kazia-therapeutics-a-top-10-finalist-in-anzlf-trans-tasman-innovation-and-growth-awards-902186.html Fri, 06 Sep 2019 04:50:00 -0400 https://www.proactiveinvestors.com/companies/news/902186/kazia-therapeutics-a-top-10-finalist-in-anzlf-trans-tasman-innovation-and-growth-awards-902186.html Kazia Therapeutics continues to progress clinical assets into FY2020 https://www.proactiveinvestors.com/companies/news/901682/kazia-therapeutics-continues-to-progress-clinical-assets-into-fy2020-901682.html Thu, 29 Aug 2019 06:21:00 -0400 https://www.proactiveinvestors.com/companies/news/901682/kazia-therapeutics-continues-to-progress-clinical-assets-into-fy2020-901682.html Kazia Therapeutics designated name for brain cancer drug by World Health Organisation https://www.proactiveinvestors.com/companies/news/901362/kazia-therapeutics-designated-name-for-brain-cancer-drug-by-world-health-organisation-901362.html Fri, 23 Aug 2019 00:17:00 -0400 https://www.proactiveinvestors.com/companies/news/901362/kazia-therapeutics-designated-name-for-brain-cancer-drug-by-world-health-organisation-901362.html Kazia Therapeutics concludes recruitment into Part B of its phase I ovarian cancer clinical study https://www.proactiveinvestors.com/companies/news/900577/kazia-therapeutics-concludes-recruitment-into-part-b-of-its-phase-i-ovarian-cancer-clinical-study-900577.html Tue, 13 Aug 2019 01:19:00 -0400 https://www.proactiveinvestors.com/companies/news/900577/kazia-therapeutics-concludes-recruitment-into-part-b-of-its-phase-i-ovarian-cancer-clinical-study-900577.html Kazia Therapeutics to begin phase I clinical trial for cancer that has spread to the brain https://www.proactiveinvestors.com/companies/news/224237/kazia-therapeutics-to-begin-phase-i-clinical-trial-for-cancer-that-has-spread-to-the-brain-224237.html Mon, 22 Jul 2019 01:29:00 -0400 https://www.proactiveinvestors.com/companies/news/224237/kazia-therapeutics-to-begin-phase-i-clinical-trial-for-cancer-that-has-spread-to-the-brain-224237.html Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52% https://www.proactiveinvestors.com/companies/news/223644/kazia-therapeutics-substantial-holder-willoughby-capital-increases-interest-to-1752-223644.html Wed, 10 Jul 2019 06:26:00 -0400 https://www.proactiveinvestors.com/companies/news/223644/kazia-therapeutics-substantial-holder-willoughby-capital-increases-interest-to-1752-223644.html Kazia Therapeutics substantial shareholder lifts interest to 17.4% https://www.proactiveinvestors.com/companies/news/223348/kazia-therapeutics-substantial-shareholder-lifts-interest-to-174-223348.html Thu, 04 Jul 2019 08:13:00 -0400 https://www.proactiveinvestors.com/companies/news/223348/kazia-therapeutics-substantial-shareholder-lifts-interest-to-174-223348.html Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research https://www.proactiveinvestors.com/companies/news/223001/kazia-therapeutics-has-two-novel-classes-of-anti-cancer-drugs-edison-investment-research-223001.html Fri, 28 Jun 2019 02:34:00 -0400 https://www.proactiveinvestors.com/companies/news/223001/kazia-therapeutics-has-two-novel-classes-of-anti-cancer-drugs-edison-investment-research-223001.html Kazia Therapeutics to collaborate with US-based oncology foundation on clinical trials for metastatic brain cancer treatment https://www.proactiveinvestors.com/companies/news/220551/kazia-therapeutics-to-collaborate-with-us-based-oncology-foundation-on-clinical-trials-for-metastatic-brain-cancer-treatment-220551.html Mon, 20 May 2019 02:46:00 -0400 https://www.proactiveinvestors.com/companies/news/220551/kazia-therapeutics-to-collaborate-with-us-based-oncology-foundation-on-clinical-trials-for-metastatic-brain-cancer-treatment-220551.html Kazia Therapeutics gains new substantial holder in The Bank of New York Mellon https://www.proactiveinvestors.com/companies/news/219839/kazia-therapeutics-gains-new-substantial-holder-in-the-bank-of-new-york-mellon-219839.html Wed, 08 May 2019 04:56:00 -0400 https://www.proactiveinvestors.com/companies/news/219839/kazia-therapeutics-gains-new-substantial-holder-in-the-bank-of-new-york-mellon-219839.html Kazia Therapeutics releases new safety data to assist in brain cancer treatments https://www.proactiveinvestors.com/companies/news/313249/kazia-therapeutics-releases-new-safety-data-to-assist-in-brain-cancer-treatments-13249.html Wed, 08 May 2019 01:02:00 -0400 https://www.proactiveinvestors.com/companies/news/313249/kazia-therapeutics-releases-new-safety-data-to-assist-in-brain-cancer-treatments-13249.html Kazia Therapeutics' ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients https://www.proactiveinvestors.com/companies/news/219706/kazia-therapeutics--ongoing-study-confirms-higher-drug-tolerability-in-newly-diagnosed-glioblastoma-patients-219706.html Mon, 06 May 2019 04:42:00 -0400 https://www.proactiveinvestors.com/companies/news/219706/kazia-therapeutics--ongoing-study-confirms-higher-drug-tolerability-in-newly-diagnosed-glioblastoma-patients-219706.html Kazia Therapeutics studies evaluate therapeutic candidates in ovarian cancer and brain tumours https://www.proactiveinvestors.com/companies/news/219425/kazia-therapeutics-studies-evaluate-therapeutic-candidates-in-ovarian-cancer-and-brain-tumours-219425.html Wed, 01 May 2019 22:30:00 -0400 https://www.proactiveinvestors.com/companies/news/219425/kazia-therapeutics-studies-evaluate-therapeutic-candidates-in-ovarian-cancer-and-brain-tumours-219425.html Kazia Therapeutics to present positive ovarian cancer drug data at AACR annual meeting https://www.proactiveinvestors.com/companies/news/312814/kazia-therapeutics-to-present-positive-ovarian-cancer-drug-data-at-aacr-annual-meeting-12814.html Tue, 02 Apr 2019 02:45:00 -0400 https://www.proactiveinvestors.com/companies/news/312814/kazia-therapeutics-to-present-positive-ovarian-cancer-drug-data-at-aacr-annual-meeting-12814.html Kazia Therapeutics will outline anti-cancer drug development strategy at CEO Sessions https://www.proactiveinvestors.com/companies/news/214129/kazia-therapeutics-will-outline-anti-cancer-drug-development-strategy-at-ceo-sessions-214129.html Thu, 07 Feb 2019 00:35:00 -0500 https://www.proactiveinvestors.com/companies/news/214129/kazia-therapeutics-will-outline-anti-cancer-drug-development-strategy-at-ceo-sessions-214129.html Kazia Therapeutics developing unique drug to battle brain cancer https://www.proactiveinvestors.com/companies/news/311805/kazia-therapeutics-developing-unique-drug-to-battle-brain-cancer-11805.html Fri, 11 Jan 2019 15:17:00 -0500 https://www.proactiveinvestors.com/companies/news/311805/kazia-therapeutics-developing-unique-drug-to-battle-brain-cancer-11805.html Kazia Therapeutics progresses phase II clinical trial for brain cancer drug https://www.proactiveinvestors.com/companies/news/193977/kazia-therapeutics-progresses-phase-ii-clinical-trial-for-brain-cancer-drug-193977.html Wed, 28 Mar 2018 21:28:00 -0400 https://www.proactiveinvestors.com/companies/news/193977/kazia-therapeutics-progresses-phase-ii-clinical-trial-for-brain-cancer-drug-193977.html